Semler Scientific (OTCMKTS:SMLR) versus InMode (OTCMKTS:INMD) Financial Survey

Semler Scientific (OTCMKTS:SMLR) and InMode (NASDAQ:INMD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership and dividends.


This table compares Semler Scientific and InMode’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Semler Scientific 46.11% 116.92% 78.92%
InMode 30.33% 50.50% 36.58%

Institutional and Insider Ownership

11.4% of Semler Scientific shares are owned by institutional investors. Comparatively, 1.1% of InMode shares are owned by institutional investors. 14.1% of Semler Scientific shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Semler Scientific and InMode, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Semler Scientific 0 0 0 0 N/A
InMode 0 0 4 0 3.00

InMode has a consensus price target of $37.00, suggesting a potential downside of 25.16%. Given InMode’s higher probable upside, analysts clearly believe InMode is more favorable than Semler Scientific.

Valuation and Earnings

This table compares Semler Scientific and InMode’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Semler Scientific $21.49 million 13.67 $5.01 million $0.66 68.18
InMode $100.16 million 15.78 $22.37 million N/A N/A

InMode has higher revenue and earnings than Semler Scientific.

Semler Scientific Company Profile

Semler Scientific, Inc. develops, manufactures, and markets proprietary products that assist healthcare providers to evaluate and treat patients with chronic diseases in the United States. Its products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, and family practitioners, as well as healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups. It offers its products through salespersons and distributors. Semler Scientific, Inc. was founded in 2007 and is headquartered in San Jose, California.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio frequency technologies. The company offers minimally-invasive aesthetic medical products for procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. InMode Ltd. offers its products directly in the United States, Canada, the United Kingdom, Spain, and India, as well as indirectly through third-party distributors internationally. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.

Receive News & Ratings for Semler Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Semler Scientific and related companies with's FREE daily email newsletter.